全文获取类型
收费全文 | 572篇 |
免费 | 55篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 10篇 |
妇产科学 | 3篇 |
基础医学 | 75篇 |
口腔科学 | 4篇 |
临床医学 | 40篇 |
内科学 | 147篇 |
皮肤病学 | 79篇 |
神经病学 | 30篇 |
特种医学 | 26篇 |
外科学 | 103篇 |
预防医学 | 11篇 |
眼科学 | 20篇 |
药学 | 45篇 |
中国医学 | 2篇 |
肿瘤学 | 31篇 |
出版年
2024年 | 3篇 |
2023年 | 9篇 |
2022年 | 9篇 |
2021年 | 12篇 |
2020年 | 10篇 |
2019年 | 11篇 |
2018年 | 18篇 |
2017年 | 16篇 |
2016年 | 14篇 |
2015年 | 17篇 |
2014年 | 19篇 |
2013年 | 16篇 |
2012年 | 21篇 |
2011年 | 43篇 |
2010年 | 18篇 |
2009年 | 21篇 |
2008年 | 20篇 |
2007年 | 17篇 |
2006年 | 27篇 |
2005年 | 21篇 |
2004年 | 17篇 |
2003年 | 27篇 |
2002年 | 23篇 |
2001年 | 21篇 |
2000年 | 26篇 |
1999年 | 21篇 |
1998年 | 8篇 |
1997年 | 9篇 |
1996年 | 5篇 |
1995年 | 9篇 |
1994年 | 6篇 |
1993年 | 3篇 |
1992年 | 9篇 |
1991年 | 5篇 |
1990年 | 7篇 |
1989年 | 3篇 |
1988年 | 8篇 |
1987年 | 11篇 |
1986年 | 9篇 |
1985年 | 8篇 |
1984年 | 3篇 |
1983年 | 3篇 |
1982年 | 5篇 |
1981年 | 6篇 |
1980年 | 3篇 |
1979年 | 3篇 |
1978年 | 3篇 |
1975年 | 3篇 |
1946年 | 2篇 |
1945年 | 3篇 |
排序方式: 共有627条查询结果,搜索用时 15 毫秒
621.
I Bellinghausen J Knop J Saloga 《International archives of allergy and immunology》2001,126(2):97-101
Several clinical studies and animal models have shown that Th2 lymphocytes play a key role in the pathophysiology of IgE-mediated allergic immune responses like allergic rhinitis and asthma or venom anaphylaxis. Classical specific immunotherapy (SIT) that has been proven to be clinically effective can serve as a role model for immunological changes that are associated with amelioration of allergic diseases. During SIT, the Th2-dominated immune response is modified towards a Th1 response leading to a decline in allergen-specific IgE and an increase in allergen-specific IgG production. Most importantly, however, production of the immunosuppressive/-regulatory cytokine interleukin 10 (IL-10) is also induced leading to T cell tolerance and prevention of tissue inflammation. In this article the role of IL-10-producing T cells in the regulation of allergic immune responses will be discussed. 相似文献
622.
623.
Jens F. Rehfeld Filip K. Knop Ali Asmar Sten Madsbad Jens J. Holst Meena Asmar 《Scandinavian journal of gastroenterology》2013,48(12):1429-1432
AbstractObjective: Recent randomized and controlled trials of drugs derived from the gut hormone glucagon-like peptide-1 (GLP-1) show that the most frequent adverse symptoms are gastrointestinal, including gallbladder-related side effects such as cholithiasis and cholecystitis. Since the gut hormone cholecystokinin (CCK) stimulates bile secretion and regulates gallbladder motility and emptying, we examined the effect of GLP-1 on the secretion of CCK in normal subjects and patients with type 1 diabetes mellitus.Materials and methods: Plasma was sampled from 10 healthy subjects and 10 patients with diabetes. With plasma glucose concentrations clamped between 6 and 9?nmol/l, GLP-1 or saline was infused for 240?min during and after a meal. The plasma concentrations of CCK were measured with a highly specific radioimmunoassay.Results: Basal plasma concentrations of CCK were similar in the normal subjects and in the diabetes patients. During the meal, the CCK concentrations rose significantly during saline infusion, whereas the GLP-1 infusion suppressed the secretion of CCK significantly in both normal subjects and in the diabetes patients.Conclusions: The results show that GLP-1 suppresses the secretion of CCK after a meal in normal and diabetic subjects. The suppression attenuates the gallbladder contractility. Our data, therefore, offer an explanation for the increased risk of adverse gallbladder events during treatment with GLP-1-derived drugs. 相似文献
624.
In recent years, vaccination strategies using antigen-presenting cells (APC) have been under investigation. Antigen delivery using genetic immunization through ex vivo transduction of dendritic cells (DC) is supposed to enhance the induction of antitumor responses in humans by activating a broad range of peptide-specific CD8+ T cells. In this study, we compared the potential of adenoviral (Ad)-transduced versus peptide-pulsed DC to induce melanoma-antigen (Ag)-specific T-cell responses in vitro. Whereas gp100-peptide-pulsed DC induced long-lasting specific CD8+ T-cell responses against single peptides, Ad-transduced DC induced broad and strong, specific immunity against various peptides of the gp100-Ag. Surprisingly, several restimulations led to decreasing gp100-specific and in parallel to increasing anti-adenoviral T-cell responses. Nevertheless, those anti-adenoviral T-cell responses provided an "adjuvant" effect by inducing an early release of high amounts of IL-2/IFN-gamma, therewith enhancing CTL induction in the initiation phase. Based on these data, we suggest a prime/boost vaccination strategy in melanoma patients--combining the use of Ad-DC and peptide-pulsed DC--to obtain efficient and long-term antitumor T-cell responses. 相似文献
625.
Per G. Hagelqvist MD Andreas Andersen PhD Kaisar Maytham BSc Christine R. Andreasen PhD Susanne Engberg PhD Tommi B. Lindhardt PhD Julie L. Forman PhD Ulrik Pedersen-Bjergaard DMSc Filip K. Knop PhD Tina Vilsbøll DMSc 《Diabetes, obesity & metabolism》2023,25(8):2300-2309
Aim
To investigate the impact of hypoglycaemia, hyperglycaemia and glycaemic variability on arrhythmia susceptibility in people with type 1 diabetes.Materials and Methods
Thirty adults with type 1 diabetes were included in a 12-month observational exploratory study. Daytime and night-time incident rate ratios (IRRs) of arrhythmias were determined for hypoglycaemia (interstitial glucose [IG] <3.9 mmol/L), hyperglycaemia (IG >10.0 mmol/L) and glycaemic variability (standard deviation and coefficient of variation).Results
Hypoglycaemia was not associated with an increased risk of arrhythmias compared with euglycaemia and hyperglycaemia combined (IG ≥ 3.9 mmol/L). However, during daytime, a trend of increased risk of arrhythmias was observed when comparing time spent in hypoglycaemia with euglycaemia (IRR 1.08 [95% CI: 0.99-1.18] per 5 minutes). Furthermore, during daytime, both the occurrence and time spent in hyperglycaemia were associated with an increased risk of arrhythmias compared with euglycaemia (IRR 2.03 [95% CI: 1.21-3.40] and IRR 1.07 [95% CI: 1.02-1.13] per 5 minutes, respectively). Night-time hypoglycaemia and hyperglycaemia were not associated with the risk of arrhythmias. Increased glycaemic variability was not associated with an increased risk of arrhythmias during daytime, whereas a reduced risk was observed during night-time.Conclusions
Acute hypoglycaemia and hyperglycaemia during daytime may increase the risk of arrhythmias in individuals with type 1 diabetes. However, no such associations were found during night-time, indicating diurnal differences in arrhythmia susceptibility. 相似文献626.
Lærke S. Gasbjerg MD Mette M. Rosenkilde MD Juris J. Meier MD Jens J. Holst MD Filip K. Knop MD 《Diabetes, obesity & metabolism》2023,25(11):3079-3092
Tirzepatide is a unimolecular co-agonist of the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors recently approved for the treatment of type 2 diabetes by the US Food and Drug Administration and the European Medicine Agency. Tirzepatide treatment results in an unprecedented improvement of glycaemic control and lowering of body weight, but the contribution of the GIP receptor-activating component of tirzepatide to these effects is uncertain. In this review, we present the current knowledge about the physiological roles of the incretin hormones GLP-1 and GIP, their receptors, and previous results of co-targeting the two incretin hormone receptors in humans. We also analyse the molecular pharmacological, preclinical and clinical effects of tirzepatide to discuss the role of GIP receptor activation for the clinical effects of tirzepatide. Based on the available literature on the combination of GLP-1 and GIP receptor activation, tirzepatide does not seem to have a classical co-activating mode of action in humans. Rather, in vitro studies of the human GLP-1 and GIP receptors reveal a biased GLP-1 receptor activation profile and GIP receptor downregulation. Therefore, we propose three hypotheses for the mode of action of tirzepatide, which can be addressed in future, elaborate clinical trials. 相似文献